Predominance of TH1 Response in Tumor-Bearing Mice and Cancer Patients Treated With AS 101

Publisher Website
Google Scholar
Abstract
Background Several studies have recently suggested that the immune response to malignant growths is regulated by distinct patterns of type 2 cytokine production. These cytokines, regulating the cytotoxic T-lymphocyte response in patients with advanced cancers, may be associated with disease progression. Evidence suggests that the T Helper 1 (TH1) and T Helper 2 (TH2) types of reaction are reciprocally regulated in vivo. The immunomodulator AS101 (ammonium trichloro [dioxoethylene-O,O'] tellurate) was found to stimulate mouse and human cells to proliferate and secrete a variety of cytokines. Clinical trials using AS101 on cancer patients are now in progress.

This publication has 0 references indexed in Scilit: